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A marked increase in the rate of glycolysis is a key event in the pathogenesis of
hepatocellular carcinoma (HCC), the main type of primary liver cancer. Liver cirrhosis
is considered to be a key player in HCC pathogenesis as it precedes HCC in up to
90% of patients. Intriguingly, the biochemical events that underlie the progression of
cirrhosis to HCC are not well understood. In this study, we examined the expression
profile of metabolic gene transcripts in liver samples from patients with HCC and patients
with cirrhosis. We found that gene expression of glycolytic enzymes is up-regulated
in precancerous cirrhotic livers and significantly associated with an elevated risk for
developing HCC. Surprisingly, expression levels of genes involved in mitochondrial
oxidative metabolism are markedly increased in HCC compared to normal livers but
remain unchanged in cirrhosis. Our findings suggest that key glycolytic enzymes such as
hexokinase 2 (HK2), aldolase A (ALDOA), and pyruvate kinase M2 (PKM2) may represent
potential markers and molecular targets for early detection and chemoprevention of
HCC.
Keywords: glucose metabolism, aerobic glycolysis, the Warburg effect, liver, liver cancer
INTRODUCTION
Hepatocellular carcinoma (HCC) is the main type of primary liver cancer and the second
leading cause of cancer-related mortality worldwide, with more than 700,000 deaths every year
(El-Serag, 2011; Jemal et al., 2011; Forner et al., 2018). The incidence of HCC has risen considerably
over the last two decades, especially in United States and Europe (El-Serag, 2011; Jemal et al., 2011).
At present, treatment options mainly consist of tumor resection, liver transplant, chemotherapies
and radiologic intervention, all of which are limited to patients with early-stage disease. However,
the large majority of HCC patients are usually diagnosed at advanced stages, which lack of curative
therapies (Llovet et al., 2008; Ulahannan et al., 2014; Forner et al., 2018). Therefore, early HCC
detection and prevention are required for reducing the high mortality rate. A better understanding
of the molecular basis of HCC formation and the identification of markers are essential for the
development of preventive therapies targeting the specific HCC-promoting factors and thereby
improvement prognosis.
The development of HCC has been closely linked to cirrhosis, an inflammatory liver condition
in which the normal liver tissue is replaced by scar tissue and regenerative nodules after long-term
damage induced by various etiologies including hepatitis B (HBV) or C (HCV) viral infection,
chronic alcohol consumption or nonalcoholic fatty liver disease (Wright, 1991; Borzio et al., 1995;
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Donato et al., 2001). In fact, up to 90% of all cases of HCC
develop in patients with cirrhosis, suggesting a role for this liver
condition in the process of hepatocarcinogenesis (El-Serag, 2011;
Jemal et al., 2011; Forner et al., 2018). At the cellular level, the
occurrence of cirrhosis is tightly coupled with multiple rounds
of hepatocyte death, inflammatory responses and compensatory
hepatocyte proliferation, resulting in the formation of the
regenerative nodules surrounded by fibrous bands characteristic
of cirrhotic livers. It is now clear that the regenerative nodules
consist of a mixed population of proliferative progenitor cells,
newly generated hepatocytes and apoptosis-resistant (damaged)
hepatocytes that, overtime, are likely to develop into dysplastic
nodules, leading to the development of HCC (Borzio et al., 1995;
Schuppan and Afdhal, 2008). Therefore, cirrhosis is recognized
as a precancerous state and is important for the investigations
of molecular markers of HCC development and preventive
strategies. Although the etiology and pathological characteristics
of liver cirrhosis have been reported in fully, the underlying
molecular mechanisms of its progression to HCC are far less
unknown.
Like many other cancers, HCC develops slowly after
progressive accumulation of genetic and epigenetic alterations
in liver cells accompanied by substantial changes in energy
metabolism leading to unrestricted proliferation of mature
hepatocytes. One of the most common metabolic changes
observed in HCC cells is an increase in the rate of glycolysis
with consequent lactate production (Kitamura et al., 2011; Huang
et al., 2013; Iansante et al., 2015; reviewed in Hay, 2016). This
metabolic phenomenon, known as the Warburg effect or aerobic
glycolysis, occurs even in the presence of copious levels of oxygen
and functional mitochondria (Gatenby and Gillies, 2004; Lunt
and Vander Heiden, 2011; DeBerardinis and Chandel, 2016;
Liberti and Locasale, 2016). Indeed, under aerobic conditions,
normal differentiated hepatocytes typically metabolize glucose
into pyruvate, which is further metabolized to carbon dioxide
in the mitochondria through the tricarboxylic acid (TCA) cycle
and oxidative phosphorylation (OXPHOS) for ATP production,
whereas under low oxygen conditions, the hepatocytes convert
the pyruvate derived from glycolysis into lactate. Thus, HCC
cells seem to re-adjust their energy metabolism by shifting
toward glycolysis irrespective of oxygen availability in a manner
similar to virtually all cancer cells (Iansante et al., 2015; Hay,
2016). This metabolic shift allows the highly proliferating HCC
cells to accumulate intermediary glucose metabolites that can
be channeled into biosynthetic pathways such as the pentose
phosphate pathway (PPP), which generates the cellular reductant
NADPH and macromolecules (nucleotides, amino acids, and
fatty acids) required for the doubling of biomass, and to suppress
apoptosis (Jones and Thompson, 2009; Hay, 2016; Kowalik et al.,
2017). There is ample evidence that the readjustment of cell
metabolism occurs as a consequence of activation of oncogenes
or loss of tumor suppressors that influences the expression and
activities of metabolic enzymes to stimulate glucose consumption
(Hay, 2016). Moreover, an increased rate of glucose uptake,
which is due to an up-regulation of the main glucose transport
GLUT1, is also a remarkable feature observed in HCC cells (Hay,
2016). Nevertheless, limited data are available on altered gene
expression of the enzymes involved in glycolysis and oxidative
mitochondrial metabolism in vivo. In addition, whether the
aerobic glycolytic metabolism is operative in the early stage of
the hepatic carcinogenesis particularly in cirrhosis and correlates
with poor patient prognosis have not been completely elucidated.
Such a background prompted us to investigate the expression
level of enzymes required for the glycolytic and mitochondrial
metabolism in liver samples from patients with cirrhosis and
patients with HCC available from six open source data sets.
MATERIALS AND METHODS
Data Sets Review
Differential gene expression analyses involving multiple clinical
samples were performed using different data sets available
through Gene Expression Omnibus (GEO) database (Barrett,
2013). Independent of age, gender, race, and region, we selected
one HCC data set (GSE36376) and three cirrhotic data sets
(GSE25097, GSE6764, and GSE14323) (accessed on March–May
2018) (Wurmbach et al., 2007; Sung et al., 2012; Lim et al.,
2013; Levy et al., 2016) as they contained the largest cohort
of HCC livers compared to adjacent non-tumor livers and
cirrhotic livers compared to normal healthy livers, respectively.
The GSE36376 data set consists of tumor and adjacent non-tumor
liver tissues containing no necrosis or hemorrhage from 240
primary HCC patients who were treated with surgical resection or
liver transplantation. None of the patients received preoperative
chemotherapy (Lim et al., 2013). The GSE25097 data set consists
of six liver specimens from healthy donors and 40 cirrhotic
livers (Sung et al., 2012). The GSE6764 data set consists of 13
HCV-associated cirrhotic liver tissues compared with healthy
livers of 10 patients undergoing resection: one patient for
hepatic haemangioma, three for focal nodular hyperplasia, two
for adenoma/cystadenoma, one for neuroendocrine tumor, and
one living donor liver transplantation (Wurmbach et al., 2007).
The GSE14323 data set consists of 41 HCV-associated cirrhotic
liver tissues compared with healthy livers of 18 patients (Levy
et al., 2016). For HCC, we also used a second independent
data set from The Cancer Genome Atlas-Liver Hepatocellular
Carcinoma (TCGA-LIHC) database, which contained a cohort
of more than 350 HCC samples compared to 50 normal healthy
livers (Ally et al., 2017). The TCGA-LIHC data set consists of
surgical resection of biopsy biospecimens collected from patients
diagnosed with HCC, and had not received prior treatment
for their disease (ablation, chemotherapy, or radiotherapy).
Each frozen primary tumor specimen had a companion normal
tissue specimen (blood or blood components, including DNA
extracted at the tissue source site). Pathology quality control
was performed on each tumor and normal tissue specimen.
Haematoxylin and eosin (H&E) stained sections from each
sample were subjected to independent pathology review to
confirm that the tumor specimen was histologically consistent
with the allowable HCCs and the adjacent tissue specimen
contained no tumor cells. Adjacent tissue with cirrhotic changes
was not acceptable as a germline control (Ally et al., 2017).
The data set GSE15654 was used for the HCC risk-association
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FIGURE 1 | Glycolytic genes are overexpressed in HCC. (A) A simplified representation depicting the glycolytic pathway in liver tumors. Abbreviations of the
enzymes are as follows: hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), phosphofructokinase liver isoform (PFKL), aldolase A (ALDOA), glyceraldehyde 3
phosphate dehydrogenase (GAPDH), phosphoglycerate kinase 1 (PGK1), phosphoglycerate mutase 1 (PGAM), enolase 1 (ENO1), and pyruvate kinase M2 (PKM2),
lactate dehydrogenase (LDH). Abbreviations of the metabolites are as follow: glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), fructose 1,6-biphosphate
(F1,6BP), glyceraldehyde 3-phosphate (GAP), and dihydroxyacetone phosphate (DHAP), 1,3-biphosphoglycerate (1,3BPG), glycerol-3-phosphate (3-PG),
glycerol-2-phosphate (2-PG), phosphoenolpyruvate (PEP). (B) Scatterplots showing the transcript levels of different glycolytic enzymes in the clinical data set
GSE36376 consisting of HCC (n = 240) and adjacent non-tumor (n = 193) liver tissue (Lim et al., 2013). The horizontal lines indicate mean ± SEM P-values were
calculated by non-parametric Mann–Whitney tests. (C) Boxplots showing differential gene expression of glycolytic enzymes among normal liver tissues (n = 50) vs.
primary tumor tissues (n = 371) (TGA-LIHC samples) analyzed using the UALCAN bioinformatic tool of genomic database (Ally et al., 2017; Chandrashekar et al.,
2017). Values are expressed as transcript per million. For each box plot, the whiskers represent the 2.5–97.5th percentile range of values, the lower and up
boundaries denote the 25th and the 75th percentile of each data set, respectively, and the horizontal line represents the median value for each group. P-values were
calculated by t-test.
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of cirrhotic patients. The data set consists of 216 livers from
patients with hepatitis C-related early-stage (Child-Pugh class A)
cirrhosis who were prospectively followed up for a median of
10 years (Hoshida et al., 2013). Clinicopathological features of
each cohort analyzed in this study are shown in the relevant cited
studies.
Data Sets Analyses
For the analyses of GEO data sets, the raw data of each data
set was downloaded from GEO accession links. Samples of each
data set were categorized into two groups: diseased patients
versus control tissue. The differential expression of genes between
the two groups was calculated using a non-parametric Mann–
Whitney U test, assigning a specific threshold (P-value <0.05).
The analyses were performed in Prism GraphPad packages, as
previously reported (Barbarulo et al., 2013).
For the differential gene expression analyses of TGCA-LIHC
we used a user-friendly, interactive web resource for analyzing
cancer transcriptome data accessible at http://ualcan.path.uab.
edu/index.html (accessed on April/May 2018) (Chandrashekar
et al., 2017). For the overall survival plots of the TGCA-
LIHC data set we used GEPIA, a newly developed interactive
web server available at http://gepia.cancer-pku.cn/index.html
(accessed on April/May 2018) (Tang et al., 2017). KM plotter
(available at http://kmplot.com/analysis/index.php?p=service&
cancer=liver_rnaseq) (accessed on August 2018) was used to
generate Kaplan-Meyer plots of an additional liver HCC data
set (Szász et al., 2016). In both cases, the median value of gene
expression was used to arrange the low and high expression
groups. The overall survival significance between the two groups
was calculated using Log-rank test, assigning a specific threshold
(P-value <0.05).
RESULTS
A salient feature of HCC cells is that they adjust their metabolic
profile to fulfill the bioenergetics and anabolic demands of the
high rates of proliferation (Kitamura et al., 2011; Huang et al.,
2013; Iansante et al., 2015; Hay, 2016). Yet, little is known
about the metabolic changes at premalignant stages of disease.
To have a complete overview of the metabolic genes expressed
in HCC and premalignant stages of disease, we analyzed the
transcription profiling of enzymes involved in glycolysis, PPP,
TCA, and OXPHOS in liver samples from patients with HCC and
patients with cirrhosis.
Gene Expression of Glycolysis and PPP
Enzymes in HCC
The glycolytic pathway consists of ten enzymatic reactions
through which glucose is converted into pyruvate. Among
the multiple isoforms of enzymes that catalyze each glycolytic
reaction, we evaluated mRNA expression levels of those that
are predominantly expressed in the liver (Figure 1A; Gatenby
and Gillies, 2004; Lunt and Vander Heiden, 2011; Hay,
2016). As shown in Figure 1B, expression of the majority
of glycolytic transcripts, including the rate limiting glycolytic
enzyme HK2 [hexokinase 2], ALDOA [aldolase, fructose-
bisphosphate A], PFKL [6-phosphofructokinase, liver type],
GAPDH [glyceraldehyde 3-phosphate dehydrogenase], PKM2
[pyruvate kinase M2]) was significantly increased in HCC livers
compared to their adjacent non-tumor tissues (P < 0.0001).
An exception was the expression of PGAM1 transcripts that
was still significantly higher (P = 0.0021) but with a less extent
compared to other enzymes. LDHA [lactate dehydrogenase
A] enzyme converts pyruvate into lactate in a reaction that
generates NAD+, diverting glycolysis-derived pyruvate from the
mitochondrial oxidative pathway (Gatenby and Gillies, 2004;
Hay, 2016). As such, the decreased expression and activity of
LDHA would favor the routing of pyruvate into mitochondria
where it can be further metabolized through TCA and oxidative
phosphorylation. Expression of LDHA was significantly reduced
in HCC samples compared to their adjacent non-tumor tissues.
In contrast, mRNA expression of the other lactate dehydrogenase
isoform, LDHB, showed no significant changes (P = 0.0797;
data not shown). Similar results were also obtained in The
Cancer Genome Atlas (TCGA) dataset consisting of 371 primary
HCC tumors and 50 normal liver samples (LIHC cohort) (Ally
et al., 2017). We observed significantly higher expression of all
glycolytic enzymes in primary HCC samples compared with
normal livers; the only exceptions were LDHA and LDHB
(Figure 1C and data not shown).
We also evaluated the mRNA levels of enzymes involved in
the oxidative phase of PPP. In this phase, two molecules of
NADP+ are reduced to NADPH, utilizing the energy from the
conversion of glucose-6-phosphate into ribulose 5-phosphate,
which then enter the non-oxidative phase leading to precursors
of nucleotide synthesis (Figure 2A; Hay, 2016; Kowalik et al.,
2017). We found that in HCC samples the transcript levels of
the rate limiting enzyme glucose-6-phosphate dehydrogenase
(G6PD) were significantly higher than those in adjacent non-
tumor (P < 0.0001) and normal livers (P < 0.0001) samples,
respectively (Figures 2B,C). Similar to G6PD, mRNA levels of the
other two enzymes involved in the oxidative phase of the PPP,
6-phosphogluconolactonase (PGLS) and 6-phosphogluconate
dehydrogenase (PGD), were higher in HCC samples compared
to control tissue (Figures 2B,C). Altogether these analyses are
consistent with an increase in glycolysis and PPP pathways,
leading to sustained ATP and cellular building blocks production
both needed for abnormal hepatocytes proliferation (Gatenby
and Gillies, 2004; Kowalik et al., 2017).
Gene Expression of Enzymes Involved in
Mitochondrial Oxidative Metabolism in
HCC
Once in the mitochondria, pyruvate can be converted into
acetyl-CoA by the pyruvate dehydrogenase (PDH) complex.
Acetyl-CoA then enters into the TCA cycle to generate NADH
and FADH2, which transfer their electrons to the electron
transport chain to generate ATP through OXPHOS (Lunt and
Vander Heiden, 2011; Ahn and Metallo, 2015; Liberti and
Locasale, 2016). In two distinct data sets, we observed that
in HCC liver samples the expression of PDHA1 gene, which
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FIGURE 2 | Expression of genes in pentose phosphate pathway (PPP). (A) Diagram of the oxidative phase of the PPP. Abbreviations of the enzymes are as follows:
glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconolactonase (PGLS), 6-phosphogluconate dehydrogenase (PGD). Activation of the two
dehydrogenase enzymes, G6PD – the rate-limiting enzyme – and PGD, results in the production of NADPH, H+ ions, and ribose 5-phosphate. (B,C) Gene
expression analyses showing enhanced expression of G6PD, PGLS, and PGD in primary HCC tumor samples compared to either adjacent non-tumor samples in
GSE36376 data set (B) or normal liver tissues in TGA-LIHC data set (C), respectively. P-values were calculated by nonparametric Mann–Whitney tests in (A) or by
t-test (B).
encodes the E1 alpha 1 subunit of the PDH complex, was
significantly higher than that in non-tumor tissue (P < 0.0001)
or normal livers (P < 0.0001), while in HCC samples the
expression of the succinate dehydrogenase (SDHB), which
converts succinate into fumarate in the TCA, was significantly
lower than that in non-tumor tissue (P< 0.0001) or normal livers
(P < 0.0001) (Figures 3A,B). These observations are consistent
with a recent study showing that decreased expression levels
of SDHB in HCC promote the Warburg effect (Tseng et al.,
2018). Less clear was the gene expression pattern of the isocitrate
dehydrogenases 2 (IDH2), which converts isocitrate to alpha-
ketoglutarate in the TCA. Expression levels of IDH2 were higher
in HCC samples compared to adjacent non-tumor samples
(P = 0.0010) from the GSE36376 data set, while IDH2 expression
showed no changes in the TGA-LIHC data set (P = 0.7106)
(Figures 3A,B).
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 October 2018 | Volume 6 | Article 138
fcell-06-00138 October 26, 2018 Time: 17:53 # 6
Lee et al. Increased Glycolysis Is Predictive of HCC Development
FIGURE 3 | Gene expression analysis of the oxidative mitochondrial metabolism in HCC. (A,C) Scatterplots showing the transcript levels of representative TCA (A)
and OXPHOS (C) enzymes in the clinical data set GSE36376 consisting of HCC (n = 240) and adjacent non-tumor (n = 193) liver tissue (Lim et al., 2013). The
horizontal lines indicate mean ± SEM P-values were calculated by nonparametric Mann–Whitney tests. (B,D) Boxplots showing differential gene expression of TCA
(B) and OXPHOS (D) among normal liver tissues (n = 50) vs. primary tumor tissues (n = 371) (TGA-LIHC samples) analyzed using the UALCAN bioinformatic tool of
genomic database (Ally et al., 2017; Chandrashekar et al., 2017). Values are expressed as transcript per million. For each box plot, the whiskers represent the
2.5–97.5th percentile range of values, the lower and up boundaries denote the 25th and the 75th percentile of each data set, respectively, and the horizontal line
represents the median value for each group. P-values were calculated by t-test.
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Oxidative phosphorylation is coupled with the electron
transport, which is organized into four large membrane-
embedded proteins complexes I to IV (Alberts et al., 2002),
to generate ATP. As recent studies have shown that certain
types of cancer rely on both glycolytic and mitochondrial
metabolism for ATP production (Lunt and Vander Heiden, 2011;
Liberti and Locasale, 2016; Gentric et al., 2017), we examined
whether this was the case for HCC. We analyzed the expression
profile of representative genes involved in the formation of
the electron transport chain complexes including NDUFA5
(complex I), UQCRB (complex III), and COXA5 (complex IV).
Except for COXA5, expression of NDUFA5 and UQCRB were
either constant (NDUAF5; P = 0.4934) or significantly reduced
(UQCRB; P < 0.0001) in HCC when compared to adjacent non-
tumor tissue in the GSE36376 cohort (Figure 3C). However, the
expression levels of all three genes showed a significant increase
in HCC samples compared to normal liver samples (Figure 3D).
Collectively, our results indicate that in HCC livers the
expression of genes involved in the glycolytic and oxidative
metabolism is higher relative to normal livers, while the
expression of oxidative metabolic genes is either comparable
or reduced compared to surrounding non-tumor tissue
(Figures 1–3). Because HCC develops in the settings of cirrhosis,
it is likely that surrounding non-tumor tissue is indeed a cirrhotic
tissue with the presence of tumor nodules nearby (Hoshida et al.,
2013). Therefore, the apparent discrepancy between the results
obtained from our analysis of the two distinct data sets may
reflect diverse microenvironments that differentiate a normal
liver from an adjacent-to-tumor liver.
Importantly, Idle and colleagues (Beyoglu et al., 2013) have
measured the expression of different tissue metabolites (including
glucose, glycerol-3 and 2-phosphate, malate, alanine) in a panel
of 31 HCC livers and found that in HCC there is a four-fold
increase in glycolysis over mitochondrial OXPHOS compared to
corresponding non-tumor liver tissue. These tissue metabolomic
studies are in line with our analyses whereby changes in transcript
expression of glycolysis, but not OXPHOS, in HCC are consistent
with a Warburg-type metabolism.
Expression of Glycolysis and PPP
Enzymes Correlates With Poor Patient
Survival in HCC
We next evaluated the prognostic value of key regulators
of aerobic glycolysis and mitochondrial metabolism in HCC
dataset (TCGA-LIHC) through the online tool GEPIA, a
web server for cancer and normal gene expression profiling
and interactive analyses (Tang et al., 2017). The cumulative
patient survival curves were investigated using the Kaplan-
Meier method, and differences in survival times were calculated
according to the log-rank test. As shown in Figure 4A, when
HCC patients were divided into two groups according to the
median value of each gene transcript that is HK2, PKM2,
ALDOA, and LDHA we found that the overall survival rate
was significantly lower in the high expression groups in the
TCGA-LIHC patient cohort (P < 0.05). Similar trends were
also detected for other glycolytic genes with some reaching
sufficient significance (P < 0.05; i.e., GAPDH, PGK1, ENO1)
and very few not reaching significance (GPI, P = 0.100;
PGAM1, P = 0.052; LDHB, P = 0.058) (data not shown).
On the contrary, PFKL follows an inverse trend. High
expression of PFKL was, indeed, inversely associated with
poor overall survival, but this was not statistically significant
(P = 0.420) (Figure 4A). Moreover, although in our differential
gene expression analyses LDHA mRNA expression was not
sufficiently higher in HCC livers compared to healthy and
surrounding non-tumor livers (Figures 1B,C), it seems that
LDHA expression has a prognostic value in HCC (Figure 4A).
This is in agreement with previous studies demonstrating
that high level of serum LDH is associated with poor
patient overall survival in several malignancies, including HCC
(Wulaningsih et al., 2015).
In examining the individual genes functioning in the oxidative
phase of the PPP, we found that the overall survival rate was
significantly lower in the group of patients that expressed high
levels of G6PD, the rate-limiting enzyme of the PPP, and PGD
mRNA (Figure 4B). Of note, although the expression of PGLS
had no prognostic value (P = 0.055; Figure 4B), it seems that
at least the rate-limiting enzyme G6PD of the oxidative phase
of PPP has important clinical implications for patients with
HCC. Surprisingly, metabolic genes involved in mitochondrial
metabolism have no prognostic value in HCC as neither the
expression of genes related to TCA cycle nor OXPHOS was
associated with poor patient overall survival (Figures 4C,D)
despite their significant increases in HCC samples compared
to normal livers (Figure 3). This could indicate that TCA and
OXPHOS enzymes may be subject to a strict post-translational
regulation that uncouple the mRNA levels from the actual
enzyme function in HCC livers.
Interestingly, similar trend was obtained by analyzing survival
of HCC patients by using a distinct data set via the KM plotter
web server tool (Szász et al., 2016) (Supplementary Figure S1).
Overall these data indicate that glycolytic genes have prognostic
role in HCC.
Gene Expression of Glycolysis and PPP
Enzymes in Cirrhotic Livers
Liver cirrhosis is a precancerous state of HCC (Wright, 1991;
Borzio et al., 1995; Donato et al., 2001; El-Serag, 2011; Jemal
et al., 2011; Forner et al., 2018). Therefore, cirrhosis is a unique
model for investigating markers for early detection of HCC
in vivo (El-Serag, 2011; Forner et al., 2018; Fujiwara et al.,
2018). To better understand the metabolic alterations in early
liver carcinogenesis, we examined the expression of glycolytic
transcripts as well as transcripts of mitochondrial metabolism
in three independent clinical data sets totalising 94 cirrhotic
livers and 34 healthy livers. We surveyed the transcripts levels
of representative glycolysis enzymes. As shown in Figure 5A,
statistically significant differences in mRNA levels were detected
between cirrhotic and normal livers for HK2, ALDOA, and
PKM2 in the three data sets analyzed. As LDHA probe was
not found in the GSE25097 cohort, we analyzed the expression
of LDHB and found that (like the other glycolytic enzymes)
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FIGURE 4 | Glycolytic gene expression is associated with poor patient prognosis. (A,B) High expression of genes associated with glycolysis and oxidative phase of
PPP significantly correlates with poor overall patients’ survival. Shown are the Kaplan-Meier overall survival curves of HCC patients according to the designated gene
expression levels above or below the median value based on TGA-LIHC data set and analyzed with the GEPIA bioinformatic tool of genomic database (Ally et al.,
2017; Tang et al., 2017). (C,D) Kaplan-Meier overall survival curves of HCC patients in TGA-LIHC data set showing homogenous prognostic significance of TCA and
OXPHOS genes.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 October 2018 | Volume 6 | Article 138
fcell-06-00138 October 26, 2018 Time: 17:53 # 9
Lee et al. Increased Glycolysis Is Predictive of HCC Development
FIGURE 5 | Gene expression of glycolysis and PPP enzymes in cirrhotic and HCC livers. (A) Scatterplots showing the increased expression of transcript levels of
representative glycolytic enzymes in cirrhotic livers compared to HCC livers and normal healthy liver tissues in three independent clinical data sets GSE25097,
GSE6764, and GSE14323 (Wurmbach et al., 2007; Sung et al., 2012; Levy et al., 2016). (B) Scatterplots showing differential gene expression of genes related to
oxidative PPP among cirrhotic livers compared to HCC livers and normal healthy liver tissues in three independent clinical data sets GSE25097, GSE6764, and
GSE14323 (Wurmbach et al., 2007; Sung et al., 2012; Levy et al., 2016). The horizontal lines indicate mean ± SEM P-values were calculated by non-parametric
Mann–Whitney tests.
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expression of LDHB was also increased in cirrhotic liver samples
compared to normal livers (Figure 5A). On the contrary,
expression levels of PFKL were significantly higher in cirrhotic
livers compared to healthy specimens in the GSE25097 cohort
(P = 0.0086) but found constant in the two other data sets
(P = 0.1824 and P = 0.9888). Collectively, these results are
consistent with those observed in HCC. Indeed, while the
expression of HK2, ALDOA, and PKM2 transcripts is increased
in HCC compared to normal livers and associated with poor
overall patient survival, elevated levels of PFKL scored in HCC
had no prognostic value (see Figure 4). This suggests that the
expression of these genes in cirrhotic livers resemble the gene
expression signature of HCC (Figure 5A).
We also evaluated the levels of transcripts encoding genes in
the oxidative phase of PPP and found that while in the GSE25097
dataset there was a significant increase of the three PPP genes
analyzed (including the rate limiting enzymes G6PD), no changes
were observed in the other two data sets, except for PGLS, whose
expression was significantly lower in cirrhotic livers (Figure 5B).
Notably, no significant increase of glycolytic and PPP gene
expression has been observed in HCC compared to cirrhotic
livers (Figures 5A,B), suggesting that reprogramming of glucose
metabolism may occur at pre-cancerous stages. For the TCA
enzymes, the mRNA levels of PDHA1, IDH2, and SHDB were
constant in both data sets of cirrhotic livers compared to normal
livers (Figure 6A). Similarly, transcripts levels of representative
OXPHOS genes that were highly expressed in HCC were not
found differentially expressed in cirrhotic livers compared to
healthy livers (Figure 6B). Collectively, these results suggest that,
in contrast to a general increase in glycolysis genes, TCA and
OXPHOS genes remained at the same level in cirrhosis. These
observations suggest a shift toward aerobic glycolysis and PPP
relative to oxidative phosphorylation in cirrhotic livers. This is
also supported by the fact that, in contrast to HCC (Figure 1),
cirrhotic livers exhibit elevated expression of LDHB compared
to healthy livers (Figure 5A), suggesting that pyruvate may be
diverted away from the mitochondria for ATP production.
Furthermore, as documented for HCC, Nishikawa et al. (2014)
demonstrated that hepatocytes isolated from liver rats with
early signs of cirrhosis shows a metabolic shift from OXPHOS
to glycolysis for the production of ATP, while normal rat
hepatocytes continue to use OXPHOS for ATP generation. It
was also shown that expression of glycolytic genes is severely
decreased in cirrhotic hepatocytes with decompensated liver
function, suggesting that failing livers do not require glycolysis to
overcome early sign of injury. Altogether these studies (Beyoglu
et al., 2013; Nishikawa et al., 2014) are in line with our analyses
whereby an increased expression of glycolysis transcripts, but not
OXPHOS transcripts, is detected in both HCC and cirrhotic livers
compared to normal livers.
Glycolytic Gene Expression in Cirrhotic
Livers Is Associated With the Risk of
Developing HCC
Next, we examined if genes involved in glycolysis, PPP, TCA cycle
and OXPHOS are associated with a progression of cirrhosis to
FIGURE 6 | Gene expression of TCA and OXPHOS enzymes in cirrhotic livers.
(A,B) Scatterplots showing homogenous expression of representative TCA
and OXPHOS biomarkers in cirrhotic livers compared to normal healthy liver
tissues in three independent clinical data sets GSE25097, GSE6764, and
GSE14323 (Wurmbach et al., 2007; Sung et al., 2012; Levy et al., 2016). The
horizontal lines indicate mean ± SEM P-values were calculated by
non-parametric Mann–Whitney tests.
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TABLE 1 | Summary of the clinical parameters associated with each group of
cirrhotic livers.
Prognosis Low HCC risk High HCC risk
HCC development rate 18% 42%
Patients’ survival rate 85% 63%
HCC and patient survival. The clinical data set GSE15654 consists
of biopsies obtained from patients with hepatitis C-related Child-
Pugh A cirrhosis who were prospectively followed in an HCC
surveillance program for a median of 10 years and classified as
low (n = 55) and high (n = 60) HCC risk based on the rates
of patient survival and incidence of developing HCC (Table 1;
Hoshida et al., 2013). We examined the expression of HK2,
PFKL, ALDOA, PKM2, and LDHB transcripts by interrogating
this public gene expression database. As shown in Figure 7A
and Table 1, high mRNA expression of HK2, PFKL, ALDOA,
and PKM2 positively correlated with a progression of cirrhosis to
HCC and a worse survival rate. An exception was LDHB, which
is not differentially expressed in the two prognostic groups.
For the oxidative phase of PPP enzymes, high G6PD mRNA
expression levels were found to be associated with a progression
of cirrhosis to HCC and reduced survival rate (P = 0.0209),
while PGLS and PGD show no differential expression (P > 0.050;
Figure 7B). Finally, in line with results showed in Figure 6,
no increase in expression of the metabolic genes in TCA cycle
and OXPHOS was observed between the low and high HCC
risk groups (Figures 7C,D). On the contrary, the expression
of IDH2, SDHB, and COXA5 were inversely correlated with
poor prognosis (Figures 7C,D). Thus, in cirrhotic livers high
expression of glycolysis genes is associated with an elevated risk
of developing HCC, suggesting that the glycolytic phenotype has
a possible prognostic role in cirrhotic patients. Moreover, HK2,
PFKL, ALDOA, PKM2, and LDHB levels show a weak differential
expression in cirrhotic and HCC livers (Figure 5A), indicating
that the acquisition of a glycolytic phenotype occurs during both
initiation and maintenance of HCC. Collectively, these results
suggest that glycolytic enzymes may represent potential targets
for HCC chemoprevention.
DISCUSSION
In more than 80% of cases HCC arise in the settings of cirrhosis
(El-Serag, 2011; Jemal et al., 2011; Forner et al., 2018; Fujiwara
et al., 2018). Therefore, understanding how cirrhosis develops
from normal liver and progresses to HCC is particularly relevant
for identifying chemoprevention therapies. Hepatitis B (HBV)
or C (HCV) viral infection, chronic alcohol consumption and
nonalcoholic fatty liver disease have been reported to be the
prominent causes of the development of cirrhosis (El-Serag,
2011). Nevertheless, the early biochemical and molecular events
that underlie the progression of cirrhosis to HCC remain largely
unclear.
Notable features of malignant hepatocytes – the predominant
liver parenchymal cells – include a high proliferative potential.
In order to proliferate HCC hepatocytes readjust their metabolic
activities to fulfill the bioenergetic and anabolic needs for
doubling mass (Gatenby and Gillies, 2004; Lunt and Vander
Heiden, 2011; Hay, 2016). It is, however, unclear how and
when HCC cells acquire these metabolic changes during the
hepatocarcinogenetic process.
Here we report changes in transcript expression of glycolysis
and PPP genes in cirrhosis consistent with a Warburg-type
metabolism and show a positive correlation between glycolytic
gene expression and the risk of developing HCC and poor patient
survival.
Compared to normal livers, elevated mRNA expression of
key metabolic genes in glycolysis, PPP, TCA, and OXPHOS
were found in livers samples from patients with HCC, implying
a pathogenic role of glucose metabolism for this disease.
A distinctive function of normal hepatocytes is the conversion
of non-carbohydrate carbon substrates, like lactate and pyruvate,
into glucose through the gluconeogenesis pathway. Several
gluconeogenic enzymes such as glucose-6-phosphatase (G6Pase),
fructose-1,6-bisphosphatase (FBP1), and PEP carboxykinase
(PEPCK) are known to bypass the first, second and third
irreversible reactions of the glycolytic pathway, respectively,
resulting in slowing down the rate of glycolysis in normal
hepatocytes (Figure 8; Hay, 2016). In HCC, G6Pase, FBP1,
and PEPCK, together with the low-affinity hexokinase 4 (HK4)
are suppressed, while the high-affinity hexokinase HK2 is
overexpressed (Wang et al., 2012; Hay, 2016). Consistent with
this, we found that HK2 is not only highly expressed in HCC
but also in cirrhosis as compared to normal liver samples,
suggesting the occurrence of the glycolytic phenotype early in the
hepatocarcinogenetic process. This hypothesis is supported by
the observation that the expression levels of other key glycolytic
enzymes such as ALDOA and PKM2 are also overexpressed
in cirrhotic livers. Among the three known isoforms of the
glycolytic enzyme aldolase (ALDOA, ALDOB, and ALDOC),
which catalyzes the reversible conversion of Fructose 1,6-
bisphosphate (F1,6BP) to Dihydroxyacetone phosphate (DHAP)
and Glyceraldehyde 3-phosphate (G3P), ALDOA catalyzes this
reaction more efficiently thus accelerating the flux through
glycolysis (Castaldo et al., 2000; Hay, 2016). Indeed, ALDOA was
reported to be the main isoform expressed in most cancer types
(Asaka et al., 1994). Our finding that the levels of ALDOA are
up regulated in cirrhotic and HCC samples suggests that a high
glycolytic phenotype is a remarkable feature of both precancerous
and cancerous conditions.
Recent works have established that the pyruvate kinase M2
isoform (PKM2), which catalyzes the synthesis of pyruvate and
ATP, using phosphoenolpyruvate (PEP) and ADP as substrates,
is a critical driver of the Warburg effect (Christofk et al., 2008;
Cortés-Cros et al., 2013; Israelsen et al., 2013; reviewed in
Wiese and Hitosugi, 2018). Indeed, similar to other types of
cancer cells, HCC cells express PKM2, the pyruvate activity
(PK) of which is maintained at low levels by pro-survival
signaling pathways (reviewed in Papa and Bubici, 2016). The
low activity of PKM2 allows the accumulation of glycolytic
intermediates that can be diverted into the biosynthetic pathways
to form amino acids, nucleic acids, and lipids (Christofk et al.,
2008; Cortés-Cros et al., 2013; Israelsen et al., 2013). While
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FIGURE 7 | Increased risk of developing HCC in cirrhotic patients significantly correlates with high expression of glycolytic genes. (A–D) Levels of transcripts in the
clinical data set GSE15654 consisting of 115 patients with newly diagnosed cirrhosis who were prospectively followed up in an HCC surveillance program and
classified as having low (n = 55) and high (n = 60) HCC risk based on the rates of patient survival and risk of developing HCC (Hoshida et al., 2013). The horizontal
lines indicate mean ± SEM P-values were calculated by non-parametric Mann–Whitney tests.
promoting these biosynthetic pathways, low PKM2 activity also
contributes to boost the levels of reduced nicotinamide adenine
dinucleotide phosphate (NADPH) and antioxidant reduced
glutathione (GSH), which serves to detoxify reactive oxygen
species (ROS) whose accumulation would result in apoptosis in
chronically injured and tumor tissues (Papa and Bubici, 2016).
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FIGURE 8 | A simplified model showing transcriptional changes in gene expression of metabolic enzymes that characterize the progression from a normal liver to
cirrhosis, which culminates in HCC. One of the most pronounced transcriptional changes during the transition from normal to HCC is the suppression of HK4 and
ALDOB followed by the induction of the high affinity HK2 and ALDOA. This allows glucose to enter in the cells and be converted into pyruvate. PKM2 and lactate
dehydrogenase (LDHA/LDHB), the last two enzymes in the glycolytic pathway, are essentially needed to maintain the high glycolytic rate of liver carcinomas by fast
removal of accumulating upstream intermediates to favor the entrance into other metabolic pathways such as the oxidative phase of PPP. Surprisingly, those
metabolic changes mostly occur early on the premalignant stage (cirrhosis) during hepatocarcinogenesis. While in cirrhotic livers glycolysis provides both biosynthetic
building blocks and anti-oxidant defenses needed for the survival (as opposed to apoptosis) of damaged cells, in livers with HCC glycolysis cooperates with
OXPHOS and TCA cycle to sustain energy needed for fast proliferation and metastasis. Our analyses suggest that the expression of glycolytic enzymes such as HK2,
ALDOA, and PKM2 (marked by asterisks) in precancerous, chronically inflamed livers may be considered as new predictive biomarkers to prevent the development
of liver cancer. Figure was created modifying illustrations provided by Servier (http://smart.servier.com) under Creative Commons Attribution 3.0 Unported License.
We indeed observed remarkable higher expression levels of
PKM2 in cirrhotic and HCC livers compared to normal livers.
Thus, although further studies are required, it is reasonable to
hypothesize that the enhanced expression of PKM2 in cirrhotic
livers may contribute to the apoptosis resistance of damaged
(injured) hepatocytes that continue to survive, proliferate and
accumulate until becoming malignant HCCs. Of note is also
the observation that the expression of LDHA (or LDHB) (the
glycolytic enzymes converting pyruvate in lactate) have no HCC
risk associated in cirrhotic patients (Figure 7), suggesting that
glycolytic-derived pyruvate may not be all converted in lactate
and is therefore channeled to other metabolic pathways (i.e.,
mevalonate pathway; discussed below).
While it was long believed that the aerobic glycolytic
phenotype is associated with an impaired mitochondrial
oxidative metabolism (Lunt and Vander Heiden, 2011), recent
research in the field have demonstrated that glycolytic and
mitochondrial metabolism are both used by cancer cells for
ATP production and macromolecule synthesis (Weinberg et al.,
2010; Ahn and Metallo, 2015; Gentric et al., 2017; Takahashi
et al., 2018). In agreement with these studies, our analysis in
HCC samples show high expression levels of genes related to
mitochondrial metabolism compared to normal livers. The fact
that in cirrhosis the expression levels of TCA and OXPHOS
genes are lower than those in normal livers or remain unchanged
suggests the occurrence of both glycolytic and mitochondrial
metabolism in HCC only. By contrast, cirrhotic livers have
high expression of HK2, ALDOA, PKM2, and LDHB as well
as display a significant increase in G6PD expression. It appears
that metabolic readjustments (that is, glycolysis shift) occur in
cirrhosis.
This may actually be explained by the fact that chronically
injured tissues such as cirrhotic livers have a more natural
tendency to trigger protective programs against ROS-inflicted
cell death (via necrosis or apoptosis), rather than mitochondrial
metabolism that contributes to the generation of ROS (Papa et al.,
2009; Luedde et al., 2014; DeBerardinis and Chandel, 2016).
Indeed, it has been suggested that in cancer cells the
production of ROS by complex I, II, and III of the electron
transport chain contributes to DNA damage and is required for
cancer cell survival, Kras-induced cellular transformation and
cancer metastasis (Weinberg et al., 2010; Takahashi et al., 2018;
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reviewed in Lunt and Vander Heiden, 2011; Reczek and Chandel,
2015; DeBerardinis and Chandel, 2016). Thus, it appears
that in inflamed livers the transcriptional regulation of genes
involved in glycolysis operates to trigger cellular protective
programs that serve to counterbalance the chronic injury. Besides
transcriptional regulation, metabolic enzymes are known to be
tightly regulated by post-transcriptional modifications including
phosphorylation, acetylation, glycosylation which affect the
metabolic cellular activities and have not been investigated
in this study. Of note, hypoxia (via activation of HIF-1α
transcription factor) and other intracellular signaling pathways
(i.e., PI3K/AKT, JNK, ERK, PTEN, p53) have also been shown to
regulate and drive the metabolic shift toward aerobic glycolysis
of HCC cells (Iansante et al., 2015; Cassim et al., 2018). It
should be instructive to evaluate the differential signature of
these metabolic regulators in normal and cirrhotic livers and test
whether these pathways are activated in cirrhotic livers. Further
studies such as protein expression analysis are therefore required
to understand the specific mechanisms underlying the metabolic
changes observed in HCC and cirrhosis, although it might be
difficult due to shortage of human cirrhotic samples available.
Prevention of HCC is an unmet medical need (El-Serag,
2011; Jemal et al., 2011; Forner et al., 2018). Interestingly, HK2,
ALDOA and PKM2 expression levels appear to have important
clinical implication for patients with cirrhosis, as analysis of
cirrhotic livers from patients followed up during a span of
10 years showed a positive correlation between high expression
of glycolysis genes and progression of cirrhosis to HCC. This
suggests that expression of these glycolytic enzymes could be used
as a new biomarker for the risk of developing HCC. By contrast,
neither TCA nor OXPHOS gene expression analyzed in this study
was associated with an increased risk of HCC.
Although there are potential limitations associated with
the nature of the analyses carried out in this study, we
sought to detect an early sign of metabolic changes in the
development of HCC and show that HK2, ALDOA and PKM2
expression levels in cirrhotic livers could be used as new
predictive biomarkers for HCC development. Early studies
demonstrated that rat cirrhotic livers show a metabolic shift from
OXPHOS to glycolysis, while normal rat hepatocytes continue
to use OXPHOS (Chen et al., 2012; Beyoglu et al., 2013;
Nishikawa et al., 2014; Gao et al., 2015). Further support to our
observations comes from ongoing clinical trials for prevention
of HCC development and recurrence. Randomized clinical
trials are currently ongoing to explore the use of statins (i.e.,
Simvastatin, Atorvastatin) to prevent either HCC development
in cirrhotic (precancerous) patients or HCC recurrence in
HCC-free patients surgically treated with curative ablation or
hepatectomy (Goodman, 2016; Chen, 2017; Fujiwara et al., 2018).
Statins are a class of lipid-lowering medications that target
the rate-controlling enzyme (NADH/NADPH-dependent) 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
of the mevalonate pathway in which cholesterol and other
isoprenoids are produced (Clendening and Penn, 2012; Fujiwara
et al., 2018). The mevalonate pathway begins with acetyl-CoA
and ends with the production of isopentenyl pyrophosphate
(IPP) and dimethylallyl pyrophosphate (DMAPP), precursors
of isoprenoids. Importantly, it has been shown that aerobic
glycolysis positively regulates the mevalonate pathway by
producing pyruvate, which is needed for the initial formation of
acetyl-CoA (Clendening and Penn, 2012). Thus, it is very likely
that by blocking the mevalonate pathway via inhibition of HMG-
CoA reductase, statins may contribute to the suppression of
aerobic glycolysis through a negative feedback (Clendening and
Penn, 2012). If these clinical trials would be beneficial to reduce
HCC risk, further studies would be necessary to directly link the
mevalonate pathways to aerobic glycolysis in liver cirrhosis.
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